To identify the time-course experiments characterizing mouse esophageal malignant progression, mice were sacrificed every 4 weeks and their esophagi were processed into H&E slides until 28 weeks (16 weeks of 4-NQO exposure and 12 weeks of sterilized drinking water). PD-1 Ab treatment After determining the approximate esophageal lesion conditions in mice at different time points during the induction of ESCC from the chemical carcinogen 4-NQO, C57BL/6J mice were randomly divided into the Cont-IgG, PD-1 Ab preventive, and PD-1 Ab treatment groups. we compared the antitumor effectiveness of PD-1 antibody treatment in mice in the ESCC stage and PD-1 antibody preventive treatment in mice in the HGIN stage. The results showed that PD-1 antibody preventive treatment efficiently impeded the progression of 4NQO-induced esophageal tumorigenesis. IHC analysis was performed to observe the infiltration of immune cells into the tumor microenvironment. It has been demonstrated that active tissue-resident memory space T cells can be induced and resided into the tumor microenvironment for a long period after treatment with PD-1 antibody. Reexposure to the oncogenic environment colonized by CD8+TRM cells can still exert antitumor effects. These results provide fresh strategies for the treatment of individuals with early stage ESCC and HGIN. Prevention Relevance: Immune checkpoint inhibitors have shown promising results in multiple tumor varieties. However, there is currently no clinical software to evaluate their therapeutic value in malignancy preventive treatment. Prophylactic use of immune checkpoint inhibitors in the early phases of ESCC may provide long-term benefits to individuals. Introduction Esophageal malignancy is one of the most common top gastrointestinal malignant tumors, and is mainly divided into two subtypes: esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC). ESCC, one of the leading causes of cancer-related deaths, accounts for more than 90% of all esophageal malignancy instances in China according to the statistics of the World Health Corporation (1). The pathogenesis of esophageal malignancy is still not fully recognized. Most studies have shown that geographical location and poor living practices, such as smoking, obesity, hot drinks, and lack of trace elements, are leading risk factors for ESCC (2, 3). Normal esophageal epithelial cells become disordered after exposure to various carcinogenic factors, going through from low-grade intraepithelial neoplasia (LGIN) to high-grade intraepithelial neoplasia (HGIN), these cells are eventually contributed to the event of ESCC (4). At present, the priority in the treatment of ESCC is surgery treatment combined with additional noninvasive treatment methods (5). The early detection rate of esophageal malignancy has gradually improved with the emergence of various tumor screening checks (6). Endoscopic treatment is just about the main treatment for individuals with early stage ESCC or HGIN because of the minimal stress to individuals (7). However, even with timely surgical treatment, the mortality rate of esophageal malignancy has not significantly decreased. The 5-yr survival rate has not exceeded 20% in the past many years (1). Wogonin The high mortality can be attributed to tumor recurrence and metastasis, which are mainly due to the lack of serosal protection of the esophagus and abundant lymph nodes under the esophageal mucosa (8). Under these unique anatomic conditions, tumor metastasis can occur in the early phases of ESCC or HGIN. In addition to the unique anatomic structure of the esophagus, the cause of tumor metastasis mainly depends on its unique immunosuppressive microenvironment. When immunosuppressive cell function prevails, the normal antitumor immune function is definitely suppressed, which causes tumor cells to escape immune system monitoring and continue to increase or metastasize distantly (9). Consequently, it is extremely important to find effective actions to reverse the event of tumors before the disease completely deteriorates. Wogonin With in-depth knowledge of Wogonin immune cells in the tumor microenvironment, scientists have produced many tumor Wogonin therapies, such as tumor vaccines, chimeric antigen receptor T-cell therapy (CAR-T), and immune checkpoint inhibitors (ICIs; ref. 10). Among these, immune checkpoint inhibitors have provided alternatives for malignancy treatment that can restore tumor-infiltrating lymphocyte’s (TIL) antitumor function and have been utilized for the treatment Akt3 of ESCC worldwide (11). Data from several ongoing clinical tests demonstrate that PD-1 antibody (Ab) monotherapy or combination chemotherapy can efficiently improve the overall survival rate of individuals with advanced ESCC (12). Neoadjuvant immunotherapy used in the perioperative period is the latest trial in the medical treatment of ESCC. Studies have found that PD-1 Ab neoadjuvant therapy can enhance the systemic immune activity of antitumor T cells and reduce the scope of tumor lesions providing strong support for subsequent surgical treatment (13). However, in medical practice, ICI therapy is definitely characterized by a delayed response, in which individuals encounter tumor remission only after a period of treatment, but the precise cause has not been exposed (14). Tissue-resident memory space T cells (TRM), which form and reside primarily in peripheral nonlymphoid organs, are a unique group of memory space T cells that use CD69 and/or Wogonin CD103 as surface markers and serve as the 1st line of defense against foreign pathogens (15). In recent years, studies have confirmed the presence of TRM cells in.